Featured Issue Briefs

The Battle on the Home Front: Jonathan Gadsden's Story

The Battle on the Home Front: Jonathan Gadsden's Story

Marine Lance Corporal's story reflects the growing need for new antibiotics that can treat dangerous diseases, against which most drugs are useless. Read More

Facilitating Medical Device Innovation: De Novo Reform

Facilitating Medical Device Innovation: De Novo Reform

The de novo process -- which requests lower-risk reclassification of medical devices and entry into the marketplace -- as it exists now is not achieving its purpose and has instead added unnecessary and time-consuming requirements. Read More

Food Products Recalled by FDA

Food Products Recalled by FDA

Since President Obama signed the FDA Food Safety Modernization Act into law, at least 149 FDA-regulated food products have been recalled due to potential pathogenic contamination. Read More

More Issue Briefs

# results: 126-150 of 204
Show items per page
Date Issue Briefs Topic
Dec 1, 2008

Defaulting on the Dream:Arizona

One in 18 homeowners in Arizona is estimated to be in foreclosure by the end of 2010, as a result of a subprime-related loan. Years of easily accessible credit and relatively low home prices that facilitated homeownership in the state have ended, leaving in their wake stricter lending terms and stagnating home appreciation.

More

Consumer Financial Security

Apr 17, 2008

Denied

An issue brief on the lack of access to federal loans by community college students. If you need to take out a loan for college, it is tough to find a better deal than a federal student loan.

More

Consumer Financial Security

Oct 3, 2006

Subprime Lending

Homeownership is the cornerstone of the American middle class and the foundation of the American dream. Low-interest rates, Wall Street demand for mortgage debt securities and new mortgage products have enabled millions of Americans to buy homes for the first time in their lives.

More

Consumer Financial Security

Apr 13, 2010

Comments Submitted to the Federal Reserve by the Pew Safe Credit Cards Project (Regulation Z, Reasonable and Proportional Penalty Charges and Other Rules Under the Credit CARD Act of 2009)

The Pew Health Group’s Safe Credit Cards Project submitted comments to the Federal Reserve Board regarding the Board’s proposed rules under Regulation Z (Docket No. R-1384).  The rules cover “reasonable and proportional” penalty charges and other requirements under the Credit CARD Act of 2009.

More

Credit Cards

Mar 23, 2010

Federal Reserve Issues Final Rules on Gift Cards

The Federal Reserve Board issued its Regulation E Final Rule on gift cards as required by the Credit Card Accountability Responsibility and Disclosure (CARD) Act of 2009. The Pew Safe Credit Cards Project submitted a letter to the Federal Reserve during its proposed rule comment period requesting that the Fed consider limiting the amount of any such monthly fee.

More

Credit Cards

Feb 22, 2010

Moving Towards Safer Credit Cards

On February 22, major new consumer protections took effect as part of the second implementation phase of the Credit Card Accountability, Responsibility, and Disclosure (CARD) Act of 2009. Just two practices addressed in this second phase will save American consumers at least $10 billion a year. The Pew Health Group's Safe Credit Cards Project is looking ahead to the third and final phase of the Credit CARD Act, to take effect August 22, 2010, which will require all credit card penalties to be “reasonable and proportional” and will direct card issuers to review all interest rate increases since the beginning of 2009.

More

Credit Cards

Nov 19, 2009

Regulatory Comment on Credit Card Disclosure Requirements

The Pew Safe Credit Cards Project submitted comments (PDF) to the Federal Reserve Board regarding the Board’s latest proposed rulemaking under Regulation Z (Docket No. R—1370). The rules implement provisions of the Credit CARD Act of 2009 that are effective February 22, 2010. Pew’s comments focused on clarifying the rights of consumers in a credit card contract and increased responsibility for and disclosure from credit card issuers.

More

Credit Cards

Sep 21, 2009

Regulatory Comment on Credit CARD Act Rule: Advanced Notice and Cancel Requirements

The Pew Safe Credit Cards Project submitted comments (PDF) to the Federal Reserve Board regarding the Board’s interim final rules under Regulation Z (Docket No. R-1364). The rules cover advance notice and right to cancel requirements under the Credit CARD Act of 2009. Pew’s comments focused on a number of exceptions the Board proposed, which could allow issuers to raise interest rates, change minimum required payment levels and impose potentially large deferred interest charges with little or no advance warning.

More

Credit Cards

Jun 25, 2009

Regulatory Comment on Credit CARD Act Reasonable and Proportional Rule

The Pew Safe Credit Cards Project submitted comments to the Federal Reserve Board in regard to rulemaking under the Credit CARD Act of 2009. These comments focused specifically on the law’s requirement that penalty fees and charges must be reasonable and  proportional to related cardholder omissions or violations.

More

Credit Cards

May 20, 2009

Curing Credit Card Penalties

Congress is set to enact new legislation that will make credit cards safer and more fair for consumers. As lawmakers negotiate final details before President Obama can sign the bill, new analysis from the Pew Health Group highlights the importance of a safeguard found only in the Senate’s version of the law.

More

Credit Cards

Oct 3, 2008

Safe Credit Card Project Regulatory Comment:

In October 2008, the Pew Safe Credit Cards Project shared comments (PDF) based on its recent work on credit cards with the Federal Reserve. Select findings from the project—including information on credit card penalty re-pricing and analysis of credit cards in the market—were included.

More

Credit Cards

Feb 27, 2014

Testimony of Elizabeth Jungman on Counterfeit Medicines

The House Energy and Commerce Subcommittee on Oversight and Investigation held a hearing on Feb 16 entitled "Counterfeit Drugs: Fighting Illegal Supply Chains." Elizabeth Jungman, director of drug safety and innovation testified on counterfeit drugs the importance that newly passed Drug Quality and Security Act will have on the safety of the U.S. pharmaceutical supply chain.

 

More

Drug Manufacturing and Distribution, Drug Safety

Feb 26, 2014

Case Studies: How Unsafe Drugs Can Reach Patients

The following case studies illustrate breaches to the pharmaceutical supply chain—the route a drug travels from its raw material origins to the delivery of a finished medicine. These examples, all of which are discussed in Pew Health Group’s report After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, demonstrate the different ways in which contaminated, fake, or otherwise unsafe medicine can reach patients, and underscore the need for reform.

More

Drug Manufacturing and Distribution, Drug Safety

Jul 30, 2013

Pew Letter to U.S. Senate in Support of S.959

Allan Coukell, senior director of drugs and medical devices, sent a letter to Senators Tom Harkin and Lamar Alexander in support of S.959, The Pharmaceutical Quality, Security and Accountability Act. If passed, the bipartisan legislation would improve patient safety by enhancing the security of the drug supply chain.

More

Drug Manufacturing and Distribution, Drug Safety

Jun 7, 2013

Pew Comment Letter to the Senate HELP Committee on Compounding Legislation

Pew sent a comment letter to the Senate Committee on Health, Education, Labor and Pensions on the Pharmaceutical Compounding Quality and Accountability Act. This bill takes steps toward clarifying state and federal oversight of compounding, including an important increase in FDA supervision of certain activities—specifically, the compounding of sterile medicines that are shipped interstate.

More

Drug Manufacturing and Distribution, Drug Safety

May 23, 2013

Pew Testimony: Examining Drug Compounding

On Thursday, May 23, the House Energy & Commerce Subcommittee on Health held a hearing, entitled "Examining Drug Compounding." Gabrielle Cosel, a drug safety expert, testified on the need to clarify oversight of compounding pharmacies on the state and federal level.

 

More

Drug Manufacturing and Distribution, Drug Safety

Apr 25, 2013

Pew Testimony to House Energy and Commerce Subcommittee on Health Regarding Drug Supply Chain

The House Energy & Commerce Subcommittee on Health will hold a hearing on April 25 entitled "Securing Our Nation’s Prescription Drug Supply Chain." Allan Coukell, a pharmacist and drug safety expert, will testify on the need to establish a national system to track and authenticate medicine. The principles outlined in his prepared testimony are supported by other stakeholders in statements from consumer, patient, public health, and industry groups.

More

Drug Manufacturing and Distribution, Drug Safety

May 16, 2012

Heparin: A Wake-Up Call on Risks to the U.S. Drug Supply

While the vast majority of drugs in American pharmacies and medicine cabinets are safe, globalization and reliance on outsourced manufacturing creates new risks, including deliberate tampering with ingredients and inadequate quality controls in plants that operate largely outside the scrutiny of the FDA.

More

Drug Manufacturing and Distribution, Drug Safety

Mar 8, 2012

Testimony of Allan Coukell on the Lack of a National Pharmaceutical Tracking System

On March 8, 2012, Pew Health Group’s Director of Medical Programs Allan Coukell testified before the Energy and Commerce Committee’s Subcommittee on Health regarding the drug distribution system – the risks of counterfeit and stolen drugs, and the pragmatic steps Congress can take to reduce those risks.

More

Drug Manufacturing and Distribution, Drug Safety

Feb 1, 2012

Testimony of Allan Coukell before the Committee on Energy and Commerce, Subcommittee on Health, United States House of Representatives

"Pew has been working to identify the risks to the drug supply and advance pragmatic solutions. In July of 2011, we released a report entitled “After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs." More

Drug Manufacturing and Distribution, Drug Safety

Sep 14, 2011

Testimony of Allan Coukell before the Committee on Health Education Labor and Pensions, United States Senate

"A major focus of the Pew Health Group is identifying ways to improve the safety of the U.S. pharmaceutical supply chain. In July of this year, we released a report entitled 'After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs.'" More

Drug Manufacturing and Distribution, Drug Safety

Aug 3, 2010

Drug Safety and Accountability Act of 2010

The Drug Safety and Accountability Act of 2010 (S.3690) seeks to strengthen industry standards to ensure the quality and safety of drugs made for the U.S. market, and to improve the U.S. Food and Drug Administration’s (FDA) oversight abilities through modernized information systems and new authorities, such as the power to order a drug recall.

More

Drug Manufacturing and Distribution, Drug Safety

Mar 10, 2010

Pew Statement on Energy and Commerce Drug Safety Hearing

"Two years after dozens of Americans lost their lives to contaminated heparin, we are still unable to protect U.S. consumers from many of the risks of pharmaceuticals manufactured in foreign factories. It is time for Congress to take action to better protect health."

More

Drug Manufacturing and Distribution, Drug Safety

Jun 10, 2009

FDA Globalization Act of 2009: Drug Safety Provisions

The Food and Drug Administration Globalization Act of 2009 (H.R.759) seeks to secure the safety of imported prescription drugs and active pharmaceutical ingredients through greater FDA authority and manufacturer responsibility, and increased inspections of prescription drug and active pharmaceutical ingredient manufacturing sites abroad.

 

More

Drug Manufacturing and Distribution, Drug Safety

May 1, 2009

Testimony of Allan Coukell, Director of the Pew Prescription Project, on Protecting Consumers from Adulterated Drugs

Protecting consumers against the risk of adulterated products is, of course, the original mission of the FDA. Today, the vast majority of pharmaceutical products sold in the United States today are not adulterated, but an increasingly complex supply chain creates new challenges and new risks – as recent events demonstrate.

More

Drug Manufacturing and Distribution, Drug Safety